CD8+ CAR Treg-cell therapy (TxCell/CRTI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD8+ CAR Treg-cell therapy (TxCell/CRTI)
Drug Alias NameCAR T-cell therapy (TxCell/CRTI)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunosuppressants
TargetsUpdating
Therapy Area/IndicationsRejection of organ transplantationMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversite de Nantes
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitut National De La Sante Et De La Recherche MedicaleUniversite de NantesSangamo Therapeutics France Sas
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A